In crisis? Call 988 then Press 1, text 838255, or chat at VeteransCrisisLine.net

If you are in crisis: contact the Veterans Crisis Line — call 988 then Press 1, text 838255, or chat at VeteransCrisisLine.net. The line is confidential.

A House Veterans’ Affairs subcommittee will hold an oversight hearing titled “Psychedelic-Assisted Therapies for Veterans: The Path Forward” on Wednesday, November 18, 2026, at 2:15 p.m. in Washington — less than a week after the U.S. Department of Health and Human Services (HHS) announced up to $4.9 million to lay the groundwork for the first U.S. clinical trials of ibogaine as a potential PTSD treatment, including for veterans. Neither step makes a psychedelic treatment available to veterans today. Both signal that federal interest in these therapies is moving quickly.

This article explains what was announced, what it does and does not mean, and what veterans living with PTSD, depression, or substance use problems can do now. It is not medical advice, and Veteran Services is not affiliated with VA, HHS, or Congress. For care options available now, see our guide: Mental health and PTSD. Search the directory: veteranservices.com/?q=PTSD.

The November 18 House hearing

The House Committee Repository lists the hearing before the Subcommittee on Health of the Committee on Veterans’ Affairs for 2:15 p.m. on November 18 in Room 360 of the Cannon House Office Building. The hearing notice describes it as an oversight hearing. Statements for the record have been posted from the Special Forces Foundation and the Veterans of Foreign Wars (VFW).

In its written statement, the VFW says VA is involved in 20 active clinical trials on psychedelic therapies for mental health conditions, and that VA has said clinical use outside research will be considered only after approval by the Food and Drug Administration (FDA). The VFW supports the research but says “veteran safety must remain the top priority,” and it asks VA to set standards for patient eligibility, informed consent, adverse-event monitoring, provider qualifications, and long-term follow-up before these therapies move beyond research settings. It also urges VA to start planning now for workforce training, facilities, and access for rural veterans in case treatments win FDA approval.

The Special Forces Foundation letter, dated November 3, 2026, says the foundation coordinates psychedelic therapy abroad for some veterans at $8,000 per veteran and that “we can’t keep up with the need.” It asks the subcommittee to press VA to pilot telehealth-supported, at-home ketamine therapy for veterans who cannot reach a VA or community care ketamine clinic. Stars and Stripes reported on the hearing and the foundation’s testimony on November 13.

HHS funds ibogaine groundwork for PTSD

On November 12, the day after Veterans Day, HHS announced investments of up to $4.9 million over five years through the Advanced Research Projects Agency for Health (ARPA-H) to advance ibogaine as a potential treatment for PTSD and other serious mental illnesses, including in veterans. HHS said VA leaders joined Secretary Robert F. Kennedy Jr. for the announcement.

According to ARPA-H, no Investigational New Drug application currently exists to legally conduct clinical research on ibogaine for psychiatric conditions in the United States. The selected teams are led by Beond, Inc., which will deliver clinical data on safety, dosing, efficacy, and durability, and the Mark Cuban Cost Plus Drug Company, which will build the foundation for a domestically manufactured ibogaine hydrochloride product for potential PTSD treatment. HHS said future awards will look at ibogaine for substance use disorders, including opioid use disorder.

HHS was clear about the limits. The awards fund regulatory and manufacturing groundwork for future trials; they do “not fund treatment of patients or human-subject research,” and they do not authorize clinical trials or establish FDA approval. HHS also warned that ibogaine “carries serious safety risks, including potentially life-threatening heart rhythm problems.” VA Secretary Doug Collins said, “Veterans deserve effective treatments and clear answers about the benefits and risks of those treatments.”

In the same announcement, the National Institute of Mental Health published a $20 million funding opportunity for a research network to study rapid-acting drugs such as ketamine, esketamine, and psilocybin. HHS said those awards will be announced in summer 2027.

What this means for veterans

These are research and oversight steps, not new benefits. VA’s own July 2026 announcement of its research partnership with HHS says VA will consider clinical use of psychedelic therapies outside research only once FDA approval is granted. VA also “strongly discourages self-medicating or attempting to replace other mental health treatment options with psychedelics or any other unprescribed substances,” and notes that proven, evidence-based treatments are available at VA facilities now.

That matters because unregulated retreats and overseas clinics are not covered by these federal efforts. HHS’s heart-rhythm warning about ibogaine is a reason to talk with a doctor before considering any such treatment.

What veterans can do now

  • Talk to your VA or community care provider about PTSD, depression, or substance use treatment options available today, and ask whether you might qualify for a VA research study.
  • Do not stop prescribed medications or replace treatment with unprescribed substances, as VA advises.
  • Follow the hearing on the House Committee Repository, where documents are posted.
  • Find help near you: search our directory for PTSD resources, or see our guides to mental health and PTSD and substance use recovery.

If you are struggling right now, you do not have to wait for new research. Call 988 then Press 1, text 838255, or chat at VeteransCrisisLine.net, any time, day or night.

Sources

Veteran Services is an independent directory. It is not affiliated with the U.S. Department of Veterans Affairs, HHS, or Congress, and it does not provide medical or legal advice. Talk with a qualified health care provider before making treatment decisions, and confirm details on the official pages linked above. Read our privacy policy and disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *